what are the limitations of the fibrate trials in residual vascular risk?
Published 2 years ago • 23 plays • Length 0:55Download video MP4
Download video MP3
Similar videos
-
1:31
what is changing in the management of residual cardiovascular risk?
-
2:04
are triglycerides related to cardiovascular risk?
-
30:12
dr peter libby - cardiac atheroma at the limits – are we fighting the final battle?
-
1:02:51
optimizing lipid risk factors: focus on residual risk, dr. david vorchheimer
-
3:57
inflammation and cardiovascular risk
-
0:53
what are the risk factors for cardiac arrhythmia?!
-
3:44
cardiovascular risk reduction in bereavement
-
9:48
tudca for bile feflux and/or gallbladder stones, as treatment. true or coax? explained
-
39:40
lp(a) and cardiovascular risk: the new kid on the block
-
15:54
cardiovascular biomarkers of atherosclerotic risk
-
14:52
raging controversies in cardiovascular risk assessment | roger blumenthal, m.d.
-
6:16
the impact of ethnicity on cardiovascular risk reduction and heart age after bariatric surgery
-
21:58
dyslipidemia and hiv
-
10:15
new guideline on the treatment of blood cholesterol
-
22:22
patient pulse: the science behind food-diet for cardiovascular risk reduction
-
26:27
the latest in treatment beyond cholesterol and statins by deepak l bhatt
-
3:35
still the one: assessment tool for 10-year risk prediction of heart disease holds true
-
13:33
how london medical detects cardiovascular risk at london medical
-
3:24
emerging risk factors & prevention of cardiovascular diseases | dr. massimo piepoli | emcure csi tv